158 related articles for article (PubMed ID: 36656871)
1. Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
Wong WB; Seetasith A; Hung A; Zullig LL
PLoS One; 2023; 18(1):e0280570. PubMed ID: 36656871
[TBL] [Abstract][Full Text] [Related]
2. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
3. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
4. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
5. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
6. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
7. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
9. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
10. The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
Ho H; Janjua NZ; McGrail KM; Harrison M; ; Law MR
PLoS One; 2021; 16(3):e0247843. PubMed ID: 33647068
[TBL] [Abstract][Full Text] [Related]
11. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
12. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
13. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
14. Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries.
Barber MJ; Gotham D; Khwairakpam G; Hill A
J Virus Erad; 2020 Sep; 6(3):100001. PubMed ID: 33251019
[TBL] [Abstract][Full Text] [Related]
15. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
Feng K; Russo M; Maini L; Kesselheim AS; Rome BN
JAMA Health Forum; 2024 Mar; 5(3):e235429. PubMed ID: 38551589
[TBL] [Abstract][Full Text] [Related]
16. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
Brouwer E; Yeung K; Barthold D; Hansen R
J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
[No Abstract] [Full Text] [Related]
17. Association of out-of-pocket pharmacy costs with adherence to varenicline.
Suehs BT; Davis C; Galaznik A; Joshi AV; Zou KH; Patel NC
J Manag Care Spec Pharm; 2014 Jun; 20(6):592-600. PubMed ID: 24856597
[TBL] [Abstract][Full Text] [Related]
18. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
20. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
